Synlogic Joins Russell 3000® Index
June 25 2018 - 7:00AM
Business Wire
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying
synthetic biology to probiotics to develop novel, living medicines,
today announced the company’s addition to the Russell 3000® Index,
following the Russell US Indices’ annual reconstitution, effective
Monday, June 25, 2018.
“We are pleased to benchmark Synlogic’s growth with our addition
to the Russell 3000 Index, which offers a platform to increase the
company’s visibility and exposure to leading institutional
investors,” said Aoife Brennan, M.B., B.Ch., Synlogic’s interim
president and chief executive officer and chief medical
officer.
Membership in the Russell 3000® Index, which remains in place
for one year, means automatic inclusion in the large-cap Russell
1000® Index or small-cap Russell 2000® Index as well as the
appropriate growth and value style indices. FTSE Russell determines
membership for its Russell US Indices primarily by objective,
market-capitalization rankings and style attributes. Russell US
Indices are widely used by investment managers and institutional
investors as the basis for index funds and as benchmarks for active
investment strategies. Approximately $9 trillion in assets are
benchmarked against Russell US Indices. Russell US Indices are part
of FTSE Russell, a leading global index provider.
For more information on the Russell 3000® Index and the Russell
US Indices’ reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About Synlogic
Synlogic is pioneering the development of a novel class of
living medicines, Synthetic Biotic medicines, based on its
proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer
probiotic microbes to perform or deliver critical functions missing
or damaged due to disease. The company’s two lead programs,
SYNB1020 and SYNB1618, target hyperammonemia as a result of liver
damage or genetic disease, and PKU, respectively. When delivered
orally, Synthetic Biotic medicines can act from the gut to
compensate for the dysfunctional metabolic pathway and have a
systemic effect, with the potential to significantly improve
symptoms of disease for affected patients. In addition, the company
is leveraging the broad potential of its platform to create
Synthetic Biotic medicines for the treatment of more common
diseases, including liver disease, inflammatory and immune
disorders, and cancer. Synlogic is collaborating with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel
disease (IBD). For more information, please visit
www.synlogictx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words “may,” “could,” “should,” “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic’s platform to
develop therapeutics to address a wide range of diseases including:
inborn errors of metabolism, liver disease, inflammatory and immune
disorders, and cancer; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; the potential
of Synlogic’s technology to treat hyperammonemia and
phenylketonuria; and the expected timing of Synlogic’s anticipated
clinical trial initiations. Actual results could differ materially
from those contained in any forward-looking statement as a result
of various factors, including: the uncertainties inherent in the
preclinical development process; the ability of Synlogic to protect
its intellectual property rights; and legislative, regulatory,
political and economic developments, as well as those risks
identified under the heading “Risk Factors” in Synlogic’s filings
with the SEC. The forward-looking statements contained in this
press release reflect Synlogic’s current views with respect to
future events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However, while
Synlogic may elect to update these forward-looking statements in
the future, Synlogic specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing Synlogic’s view as of any date subsequent to the date
hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180625005257/en/
MEDIA:SynlogicCourtney Heath,
617-872-2462courtney@scientpr.comorINVESTORS:SynlogicElizabeth
Wolffe, Ph.D., 617-207-5509liz@synlogictx.com
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Sep 2023 to Sep 2024